Showing results (141-150 of 285) with videos related to
Sort By:
Pageof 29
Liver International : Official Journal of the International Association for the Study of the Liver|June 22, 2021
New therapies for hepatitis delta virus infectionDimitri Loureiro, Corinne Castelnau, Issam Tout, et al.Expert Opinion on Drug Safety|September 5, 2012
Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studiesPatrick Marcellin, Stuart K Roberts, K Rajender Reddy, et al.Gastroenterology|March 24, 2009
Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2aPatrick Marcellin, Ferruccio Bonino, George K K Lau, et al.Journal of Hepatology|December 19, 2007
Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumptionPatrick Marcellin, Françoise Pequignot, Elisabeth Delarocque-Astagneau, et al.Romanian Journal of Gastroenterology|July 30, 2002
Role of cytokines in the assessment of the severity of chronic hepatitis C and the prediction of response to therapyManuela G Neuman, Jean-Pierre Benhamou, Asma Ibrahim, et al.Journal of Hepatology|January 16, 2007
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapyRami Moucari, Marie-Pierre Ripault, Valérie Oulès, et al.Journal of Virology|March 28, 2014
Reduction of microRNA 122 expression in IFNL3 CT/TT carriers and during progression of fibrosis in patients with chronic hepatitis CEmilie Estrabaud, Martine Lapalus, Philippe Broët, et al.Antiviral Therapy|December 25, 2009
Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2aRami Moucari, Michelle Martinot-Peignoux, Vincent Mackiewicz, et al.The Journal of Infectious Diseases|July 28, 2011
Antiviral activity of danoprevir (ITMN-191/RG7227) in combination with pegylated interferon α-2a and ribavirin in patients with hepatitis CNicole Forestier, Dominique Larrey, Patrick Marcellin, et al.Gastroenterology|November 28, 2002
Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis BVincent Di Martino, Thierry Thevenot, Jean-François Colin, et al.Pageof 29